Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APVO436 with Venetoclax and Azacitidine in Elderly/Unfit AML
NCT04973618Phase 1Withdrawn
- Sponsor
- Aptevo Therapeutics
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
01
Overview
Phase 1, open-label, single-arm trial of mipletamig in acute myeloid leukemia (AML), sponsored by Aptevo Therapeutics. Primary endpoint: Incidence of Grade 3-4 Adverse Events and Serious Adverse Events. Planned start Jan 2025; status: withdrawn.
02
Drugs
mipletamig
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04973618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04973618.